Piramel, based in India, is a branded generics company.
位于印度的Piramel公司是一家生产著名品牌通用药物的企业。
"Europe is a branded generics market and so pricing is not a major issue," he said.
欧洲是一个品牌性质的仿制药市场，所以定价不是一个主要问题，他说。
Simply put, there is significant untapped opportunity in the branded generics space.
简单地说，品牌仿制药还有很大的提升空间。
Big Pharma has long flirted with branded generics, but this time it looks like the real thing.
制药大亨们早就对品牌仿制药有意，但这次看起来像是要玩真的了。
With so much at stake, it is odd then, that branded generics have made so little headway in the world's largest drug market.
奇怪的是，在如此严峻的形势下，品牌仿制药在全球最大的药物市场却只有很小的进展。
Branded generics have the benefit of being a known entity and a recognizable name. This already differentiates them from plain generics.
品牌仿制药可以从已知的公司和响亮的名字获益，这与平常的仿制药不同。
Big Pharma has already embraced branded generics abroad; the same principles apply here. Branded generics have the ability to change the US generics landscape.
制药大亨们已经接受了国外品牌仿制药；同样的法则在这里同样适用，品牌仿制药有能力改变美国仿制药格局。
Others have gone a bit further, as Britain's GlaxoSmithKline did with its recent acquisition of a share in Aspen, an African firm specialising in branded generics.
另有一些公司走得远一些，如英国的葛兰素史克最近收购了一家非洲品牌仿制药公司阿斯彭aspen的股份。
The real action now is in branded generics, which command a premium in many emerging markets due in part to the fear that unknown products might be fake or of dubious quality.
目前的核心仍然在非专利品牌药品市场，因为担心市场上没牌子的药是假药或者质量不可靠，所以人们纷纷购买品牌药，这使得品牌药在许多新兴市场的需求增大。
But Pharma is looking beyond the US borders for growth in the branded generics market. The world market for generic drugs now averages 25% of all drug sales - higher still in emerging markets.
但是制药公司正在展望美国之外品牌仿制药市场的增长，仿制药目前占全球市场平均份额的25%，在新兴市场则更高。
Mark Mandel, a father in Chicago, says his family previously bought infants’ Tylenol and Motrin drops on the assumption that the branded products were of better quality than generics.
芝加哥的马克·曼德尔，是一位父亲。他说，过去觉得强生是名牌，比普通品牌的质量要高，所以他们常为小孩购买强生的泰诺和布洛芬滴液。
Kathleen Jaeger of America's Generic Pharmaceutical Association adds that branded firms try to extend their lucrative monopolies by filing less rigorous secondary patents designed “to block generics”.
美国通用药物协会的KathleenJaeger补充说很多品牌药公司制作大量的文件申请专利分案“以阻碍仿制药”。
The report looks at consumer spending on prescription drugs, and presents data on how many prescriptions have been filled, in which therapeutic areas, and compares use of generics with branded drugs.
该报告透视了处方药消费、目前处方药治疗领域数据、对仿制药和原研药的比较。
The report looks at consumer spending on prescription drugs, and presents data on how many prescriptions have been filled, in which therapeutic areas, and compares use of generics with branded drugs.
该报告透视了处方药消费、目前处方药治疗领域数据、对仿制药和原研药的比较。
应用推荐